Deals this week: Medline Industries, Atlas Genetics, Sensifree

26 January 2017 (Last Updated January 26th, 2017 18:30)

Medline Industries, through a joint partnership with medical device company, Potrero Medical, has secured long-term exclusive rights to market and distribute the latter’s Accuryn critical care monitoring system in North America.

Medline Industries, through a joint partnership with medical device company, Potrero Medical, has secured long-term exclusive rights to market and distribute the latter’s Accuryn critical care monitoring system in North America.

The partnership also continues clinical investigations to further support the benefits of Accuryn, which is claimed to be the only available technology that provides accurate and real-time data related to urine production and intra-abdominal pressure.

In a series D venture financing round, in-vitro diagnostics company Atlas Genetics has raised $35m, financed by its existing investors including Novartis Venture Funds, Consort Medical, Johnson & Johnson Innovation, Life Sciences Partners, BB Biotech Ventures, RMI Partners and Technology Venture Partners, and a new investor Wondfo Biotech.

"Accuryn, which is claimed to be the only available technology that provides accurate and real-time data related to urine production and intra-abdominal pressure."

The company will use the proceeds to conduct clinical trials for a second test to detect both Chlamydia and Gonorrhoea and for the commercial launch of the same, subject to receiving approvals from the US FDA planned towards the end of 2017.

With an aim to provide real alternative to decades-old, cuff-based blood pressure monitoring systems, Sensifree, a contact-free electromagnetic sensors developer, has joined hands with Swiss research and technology organisation, CSEM.

The research partnership will combine Sensifree's novel, RF-based approach and CSEM's expertise in blood pressure monitoring systems to create a unique, cuff-free blood pressure sensor technology tool for the healthcare wearables market.

Metabolomic Technologies has signed a multi-year, non-exclusive licensing and distribution agreement with Evolution Laboratories to provide the latter the distribution rights for its flagship product, PolypDx, in five western US states including Nevada, California, Arizona, Utah and Texas.

The agreement expands the coverage of PolypDx, a urine-based diagnostic test for detection of adenomatous polyps, helps preventing colon cancer in the western US, and ensures better access to all patients.

The earlier exclusive, licensing and distribution agreement signed by the company with Atlantic Diagnostic Laboratories introduced the test in 12 eastern US states in May 2016.